Unit:
Κατεύθυνση Καρκίνος Πνεύμονα: Σύγχρονη Κλινικοεργαστηριακή Προσέγγιση και ΈρευναLibrary of the School of Health Sciences
Author:
Σιούτας Απόστολος
Original Title:
Ασφάλεια χορήγησης της πεμετρεξίδης
Summary:
Aim:
To prescribe the clinical and laboratory side efects of the use of pemetrexed
as chemotherapeutic drug in lung cancer.
Methods:
In this retrospective study were included 69 patients with lung cancer who
received pemetrexed as chemotherapy drug, presented side effects and visited
sotiria chest hospital from September 2009 until Octomber 2011. For every
patient were recorded , demographic elements, comorbidities, stage of the
disease, type of therapy, need for hospitalisation, need for adjustment of the
drugs granted and the final result. For every side effect it was noted the date
of appearance, duration, intensity, grade and development.
Results:
No statistical important difference in side effects was noted in addition with:
The line of chemotherapy, the disease stage, the chemotherapy drugs used, the
comorbidities. Patients which recieved greater dose of pemetrexed appeared
to have more side effects no statisticaly important. In thirteen patients down
adjument was needed. In ten patients day hospitalisation was needed. No one
stopped chemotherapy. No death was noted.
Conclusion:
Aggrement with bibliography for high security in administration of the drug in
lung cancer. Disadvantages of the study: Small number of patients,
administration of combination of chemotherapeutic drugs and the participation
of the course of the disease.
Keywords:
Pemetrexed, NSCLC, Αdenocarcinoma, Safety, Side effects
File:
File access is restricted only to the intranet of UoA.
document.pdf
1 MB
File access is restricted only to the intranet of UoA.
